O002/#43 Randomized Phase 3 Study of Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer (Aec): Subgroup Analysis of Patients with Dna Mismatch Repair Deficient (Dmmr) Tumors
AuthID
P-00V-TAV
P-00V-TAV